Supplementary file: Examples of Clinical pharmacist interventions in transplanted patients and candidates for transplantation with COVID-19

## Type of interventions

CNIs† reduced dose in concomitant use of other medications

Tacrolimus dose adjustment in accordance with PIs<sup>‡</sup>

Cyclosporine dose adjustment in accordance with HCQ§

Cyclosporine dose adjustment in accordance with Pls

Tacrolimus dose adjustment in accordance with Antifungal azoles

Immunosuppressive or anti-viral discontinuation according to patient's clinical status

Discontinuation of anti-metabolite medications regarding sever leukopenia

Discontinuation of Tocilizumab due to increasing of hepatic enzymes by 5 times

Discontinuation of Tocilizumab in patients with ANC<sup>¶</sup> lower than 500 /mm<sup>³</sup>

Discontinuation of HCQ due to QT interval prolongation of more than 500 milliseconds

Discontinuation of mTOR# inhibitor due to severe progression of COVID-19

Discontinuation of HCQ in patients with G6PD<sup>††</sup> deficiency

Dose adjustment according to kidney function

Antibiotics adjustment in HD<sup>‡‡</sup> patients

Antibiotics adjustment in CRRT§§ setting

CNIs dose adjustment in the setting of AKI<sup>III</sup>

Remdesivir dose adjustment in patients with GFR##<30

Dose adjustment according to hepatic function

Statins dose adjustment regarding liver enzyme elevations

Valproate dose adjustment in moderate liver function

Discontinue or modify medications due to potential DDIs<sup>†††a</sup>

NOACs<sup>‡‡‡</sup> and PIs

Favipiravir and HCQ

Methadone and PIs

NSAIDs and Warfarin

Fluoxetine and Linezolid

Pls and Everolimus

Intravenous-to-oral antibiotic switch

## Start of anticoagulant

†Calcineurin inhibitor; †Protease inhibitors; §Hydroxychloroquine; ¶Absolute neutrophil count; #Mammalian Target of Rapamycin; ††Glucose-6-phosphate dehydrogenase; ‡†Hemodialysis; §§Continuous renal replacement therapy; ¶¶Acute kidney injury; ##Glomerular filtration rate; †††drug-drug interaction; ‡‡†New oral anticoagulants; \*Potential DDIs: Drug-drug interaction type D or X